Detalle Publicación

ARTÍCULO
Twelve-month strogen levels in premenopausal women with hormone receptor-positive breast cancer Receiving sdjuvant triptorelin plus exemestane or tamoxifen in the suppression of ovarian function trial (SOFT): The SOFT-EST substudy
Autores: Bellet, Meritxell; Gray, Kathryn P.; Francis, Prudence A.; Lang, Istvan; Ciruelos, Eva; Lluch, Ana; Angel Climent, Miguel; Catalan, Gustavo; Avella, Antoni; Bohn, Uriel; González Martín, Antonio; Ferrer, Roser; Catalan, Roberto; Azaro, Analia; Rajasekaran, Agnita; Morales, Josefa; Vazquez, Josep; Fleming, Gini F.; Price, Karen N.; Regan, Meredith M.
Título de la revista: JOURNAL OF CLINICAL ONCOLOGY
ISSN: 1527-7755
Volumen: 34
Número: 14
Páginas: 1584-93
Fecha de publicación: 2016
Resumen:
During the first year, most patients on exemestane plus triptorelin had E2 levels below the defined threshold of 2.72 pg/mL, consistent with levels reported in postmenopausal patients on aromatase inhibitors, but at each time point, at least 17% of patients had levels greater than the threshold.